Graves' Disease (Overactive Thyroid) Market Regional Analysis by 2029
Graves' disease (overactive thyroid), sometimes known as Basedow's disease, is an autoimmune condition that leads to hyperthyroidism. It occurs when the body's immune cells attack the thyroid, causing excessive thyroid hormone production. Graves' disease treatment aims to inhibit thyroid hormone production and block the hormones' effects on the body. Beta-blockers including propranolol and metoprolol are frequently used as first-line treatments. These medications help to keep your heart rate in check and safeguard it until other hyperthyroidism treatments take effect. Antithyroid drugs like methimazole (Tapazole) and propylthiouracil stop the thyroid gland from producing thyroid hormone. Radioiodine therapy entails taking a single dose of radioactive iodine in the form of a pill or a liquid. Radiation kills thyroid gland cells over a period of two to three months.
Graves' disease is an immune system condition characterized by excessive thyroid hormone production (hyperthyroidism). Graves' disease is a common cause of hyperthyroidism, though a variety of conditions can cause it. Graves' disease has a wide range of signs and symptoms because thyroid hormones affect many different body systems. Graves' disease can affect anyone, however it is more common in women and those under the age of 40.
Data Bridge Market Research analyses that the Graves' disease (overactive thyroid) market was valued at USD 351.55 million in 2021 and is expected to reach USD 507.65 million by 2029, registering a CAGR of 4.70% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America dominates the Graves' disease (overactive thyroid) market because of the rising prevalence of Graves' disease (overactive thyroid) and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market's growth rate.
Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/global-graves-disease-overactive-thyroid-market
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to the increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
Some of the major players operating in the Graves' disease (overactive thyroid) market are:
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Ireland)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Merck & Co., Inc. (U.S.)
Allergan (Ireland)
AstraZeneca (U.K.)
Johnson & Johnson Private Limited (U.S.)
Hikma Pharmaceuticals PLC (U.K.)
Bristol-Myers Squibb Company (U.S.)
Bayer AG (Germany)
Boehringer Ingelheim International GmbH. (Germany)
Dr. Reddy's Laboratories Ltd. (India)
Gilead Sciences, Inc. (U.S.)
Amgen Inc. (U.S.)
Eli Lilly and Company (U.S.)
AbbVie Inc. (U.S.)
Lupin (India)
Allergan (Ireland)
Other Posts:
https://www.xaphyr.com/blogs/336693/Heart-Failure-Drugs-Market-Growth-Revenue-Projection-by-2028
https://chatterchat.com/read-blog/27104
https://chandrabindu.net/read-blog/3994
https://friendsome.online/read-blog/3079
https://tannda.net/read-blog/24783
https://uchatoo.com/read-blog/19190
https://waoop.com/read-blog/71278
https://geto.space/read-blog/113339
https://afroshub.com/read-blog/31223
https://wiwonder.com/read-blog/9969
https://www.pickmemo.com/read-blog/158196
https://vherso.com/read-blog/61155
https://dbmrhealthinsights.blogspot.com/2023/05/angiotensin-converting-enzyme-ace.html
https://www.diigo.com/item/note/9wvry/qg3h?k=9dfdba09986a3cb13cda650451bf5d93
https://medium.com/@michaaelj1411/151743546f50
https://www.pearltrees.com/michaeljdbmr/dbmr-medical/id65545783/item519159110
https://markethive.com/dbmrmedical/blog/angiotensinconvertingenzymeaceinhibitorsmarketanalysisby2028
https://marketstory360.com/?p=72616&preview=true&_preview_nonce=712cfdafc4
https://beyondher.mn.co/posts/36521691
https://penzu.com/journals/27728997/88830363
https://theomnibuzz.com/angiotensin-converting-enzyme-ace-inhibitors-market-analysis-by-2028/
https://writer.zohopublic.in/writer/published/hqhpccd4a82b8544f42e0b4af9798a2dfcc69
https://elovebook.com/read-blog/8229
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Comments
Post a Comment